 |
|
Maintenance Phase Efficacy of Sertraline for Chronic Depression
A Randomized Controlled Trial
Martin B. Keller, MD;
James H. Kocsis, MD;
Michael E. Thase, MD;
Alan J. Gelenberg, MD;
A. John Rush, MD;
Lorrin Koran, MD;
Alan Schatzberg, MD;
James Russell, MD;
Robert Hirschfeld, MD;
Daniel Klein, PhD;
James P. McCullough, PhD;
Jan A. Fawcett, MD;
Susan Kornstein, MD;
Lisa LaVange, PhD;
Wilma Harrison, MD;
for the Sertraline Chronic Depression Study Group
JAMA. 1998;280:1665-1672.
Context.— The chronic form of major depression is associated with a high rate of prevalence and disability, but no controlled research has examined the impact of long-term treatment on the course and burden of illness.
Objective.— To determine if maintenance therapy with sertraline hydrochloride can effectively prevent recurrence of depression in the high-risk group of patients experiencing chronic major depression or major depression with antecedent dysthymic disorder ("double depression").
Design.— A 76-week randomized, double-blind, parallel-group study, conducted from September 1993 to November 1996.
Setting.— Outpatient psychiatric clinics at 10 academic medical centers and 2 clinical research centers.
Intervention.— Maintenance treatment with either sertraline hydrochloride (n=77) in flexible doses up to 200 mg or placebo (n=84).
Patients.— A total of 161 outpatients with chronic major or double depression who responded to sertraline in a 12-week, double-blind, acute-phase treatment trial and continued to have a satisfactory therapeutic response during a subsequent 4-month continuation phase.
Main Outcome Measure.— Time to recurrence of major depression.
Results.— Sertraline afforded significantly greater prophylaxis against recurrence than did placebo (5 [6%] of 77 in the sertraline group vs 19 [23%] of 84 in the placebo group; P=.002 for the log-rank test of time-to-recurrence distributions). Clinically significant depressive symptoms reemerged in 20 (26%) of 77 patients treated with sertraline vs 42 (50%) of 84 patients who received placebo (P=.001). With use of a Cox proportional hazards model, patients receiving placebo were 4.07 times more likely (95% CI, 1.51-10.95; P=.005) to experience a depression recurrence, after adjustment for study site, type of depression, and randomization strata.
Conclusions.— Maintenance therapy with sertraline is well tolerated and has significant efficacy in preventing recurrence or reemergence of depression in chronically depressed patients.
From the Departments of Psychiatry, Butler Hospital, Brown University, Providence, RI (Dr Keller); Cornell University School of Medicine, New York, NY (Dr Kocsis); University of Pittsburgh and Western Psychiatric Institute, Pittsburgh, Pa (Dr Thase); University of Arizona, Tucson (Dr Gelenberg); University of Texas Southwestern Medical Center, Dallas (Dr Rush); Stanford University School of Medicine, Stanford, Calif (Drs Koran and Schatzberg); University of Texas Medical Branch at Galveston (Drs Russell and Hirschfeld); State University of New York at Stony Brook (Dr Klein); Medical College of Virginia, Virginia Commonwealth University, Richmond (Drs McCullough and Kornstein); Rush Institute for Mental Well-Being, Chicago, Ill (Dr Fawcett); Quintiles, Research Triangle Park, NC (Dr LaVange); Pfizer Inc, and College of Physicians and Surgeons, Columbia University, New York, NY (Dr Harrison).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Efficacy of Sertraline in Prevention of Depression Recurrence in Older Versus Younger Adults With Diabetes
Williams et al.
Diabetes Care 2007;30:801-806.
ABSTRACT
| FULL TEXT
Sertraline for Prevention of Depression Recurrence in Diabetes Mellitus: A Randomized, Double-blind, Placebo-Controlled Trial.
Lustman et al.
Arch Gen Psychiatry 2006;63:521-529.
ABSTRACT
| FULL TEXT
Acne maintenance therapy: expanding the role of topical retinoids?
Zane
Arch Dermatol 2006;142:638-640.
FULL TEXT
Maintenance treatment of major depression in old age.
Reynolds et al.
NEJM 2006;354:1130-1138.
ABSTRACT
| FULL TEXT
A Randomized, Placebo-Controlled Trial of Sertraline for Prophylactic Treatment of Highly Recurrent Major Depressive Disorder
Lepine et al.
Am. J. Psychiatry 2004;161:836-842.
ABSTRACT
| FULL TEXT
Maintenance Treatment of Insomnia: What Can We Learn From the Depression Literature?
Jindal et al.
Am. J. Psychiatry 2004;161:19-24.
ABSTRACT
| FULL TEXT
Meta-Analysis of Placebo Rates in Major Depressive Disorder Trials
Stolk et al.
The Annals of Pharmacotherapy 2003;37:1891-1899.
ABSTRACT
| FULL TEXT
Past, Present, and Future Directions for Defining Optimal Treatment Outcome in Depression: Remission and Beyond
Keller
JAMA 2003;289:3152-3160.
ABSTRACT
| FULL TEXT
A Double-Blind, Placebo-Controlled Study of Sertraline in the Prevention of Depression in Stroke Patients
Rasmussen et al.
Psychosomatics 2003;44:216-221.
ABSTRACT
| FULL TEXT
Older community residents with depression: long-term treatment with sertraline: Randomised, double-blind, placebo-controlled study
WILSON et al.
Br. J. Psychiatry 2003;182:492-497.
ABSTRACT
| FULL TEXT
18-month maintenance treatment with sertraline may have sustained psychosocial benefits in chronic depression
Bech
Evid. Based Ment. Health 2003;6:49-49.
FULL TEXT
Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina
Glassman et al.
JAMA 2002;288:701-709.
ABSTRACT
| FULL TEXT
Psychosocial Outcomes Following Long-term, Double-blind Treatment of Chronic Depression With Sertraline vs Placebo
Kocsis et al.
Arch Gen Psychiatry 2002;59:723-728.
ABSTRACT
| FULL TEXT
Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression
Thase et al.
Arch Gen Psychiatry 2002;59:233-239.
ABSTRACT
| FULL TEXT
National Depressive and Manic-Depressive Association Consensus Statement on the Use of Placebo in Clinical Trials of Mood Disorders
Charney et al.
Arch Gen Psychiatry 2002;59:262-270.
ABSTRACT
| FULL TEXT
Clinical importance of long-term antidepressant treatment
HIRSCHFELD
Br. J. Psychiatry 2001;179
:s4-s8.
ABSTRACT
| FULL TEXT
Prophylactic effect of citalopram in unipolar, recurrent depression: Placebo-controlled study of maintenance therapy
HOCHSTRASSER et al.
Br. J. Psychiatry 2001;178:304-310.
ABSTRACT
| FULL TEXT
Managing Depression in Medical Outpatients
Whooley and Simon
NEJM 2000;343:1942-1950.
FULL TEXT
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
Keller et al.
NEJM 2000;342:1462-1470.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder: A Randomized Controlled Trial
Brady et al.
JAMA 2000;283:1837-1844.
ABSTRACT
| FULL TEXT
Impact of Disseminating Quality Improvement Programs for Depression in Managed Primary Care: A Randomized Controlled Trial
Wells et al.
JAMA 2000;283:212-220.
ABSTRACT
| FULL TEXT
Sertraline: For Chronic Depression in Adults and OCD in Kids
JWatch Psychiatry 1999;1999:4-4.
FULL TEXT
Treating Depression as a Recurrent or Chronic Disease
Glass
JAMA 1999;281:83-84.
FULL TEXT
Maintenance Sertraline Averts Depression Relapse
JWatch Women's Health 1999;1999:4-4.
FULL TEXT
Sertraline Helps Prevent Recurrence of Chronic Depression
JWatch General 1998;1998:2-2.
FULL TEXT
|
